Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.

Once hailed primarily as a diabetes drug and later catapulted into stardom for its weight-loss benefits, Ozempic (semaglutide ...

Essentially, Ozempic and Wegovy are brand names for semaglutide, which is in the GLP-1 receptor agonist (GLP-1RA) drug class.

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

Nutritional counseling remains a central component of obesity treatment, even in the era of highly effective weight-loss ...

Novo Nordisk stock rose after the Danish pharma giant posted better-than-expected quarterly earnings even as sales of its ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

U.S. trade policy has also heightened investor concerns over the potential impact to Novo Nordisk's key market. U.S. President Trump has threatened to unveil tariffs on pharmaceutical products in the ...